rekrunner wrote:
Part of the "strength" of the "EPO works for everybody" is based in part on studies showing how EPO works, at least for the subjects in the study. It's "studies on the mediocre" combined with "anecdotes" at the top.
These studies, like the ones on the Scottish runners, and the Kenyan runners, and many like them, did not link performance improvements to improved recovery and harder training, but to changes in blood parameters and VO2max.
To further evaluate this idea of "recover and train harder", we would need a study that attempts to measure recovery and training load. And we would need a "fair" way to determine how much we can allow the training load to increase, for the EPO subjects, versus non-EPO controls. After all, we couldn't increase the workload of the EPO subjects, while not changing the workload of the controls, and call that fair.
Lets look at some emerging research on rHuEPO and improved time to exhaustion involving non-hematopoietic factors:
https://atlasofscience.org/rhepo-improves-time-to-exhaustion-by-non-hematopoetic-factors-in-humans/https://www.ncbi.nlm.nih.gov/pubmed/26729211Results showing that lower dose rHuEPO prolonged intense constant-load exercise (85% of VO2max) after 4 weeks of administration by about 30%, and high dose by about 73%...without higher oxygen consumption during the submaximal exercise.
Very interesting? 🤔